WO2021077681A1 - 一种用于水光注射的透明质酸凝胶组合物及其制备方法 - Google Patents
一种用于水光注射的透明质酸凝胶组合物及其制备方法 Download PDFInfo
- Publication number
- WO2021077681A1 WO2021077681A1 PCT/CN2020/082546 CN2020082546W WO2021077681A1 WO 2021077681 A1 WO2021077681 A1 WO 2021077681A1 CN 2020082546 W CN2020082546 W CN 2020082546W WO 2021077681 A1 WO2021077681 A1 WO 2021077681A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyaluronic acid
- water
- gel composition
- light injection
- acid gel
- Prior art date
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 228
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 228
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 205
- 239000000203 mixture Substances 0.000 title claims abstract description 87
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims description 21
- 238000002347 injection Methods 0.000 claims description 104
- 239000007924 injection Substances 0.000 claims description 104
- 238000000034 method Methods 0.000 claims description 33
- 239000007864 aqueous solution Substances 0.000 claims description 31
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- 239000001301 oxygen Substances 0.000 claims description 23
- 230000008569 process Effects 0.000 claims description 18
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 17
- 230000003647 oxidation Effects 0.000 claims description 11
- 238000007254 oxidation reaction Methods 0.000 claims description 11
- 230000009471 action Effects 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 230000003020 moisturizing effect Effects 0.000 abstract description 26
- 230000000694 effects Effects 0.000 abstract description 17
- 230000036548 skin texture Effects 0.000 abstract description 5
- 238000009827 uniform distribution Methods 0.000 abstract description 4
- 238000007920 subcutaneous administration Methods 0.000 abstract description 3
- 230000005923 long-lasting effect Effects 0.000 abstract description 2
- 239000000499 gel Substances 0.000 description 88
- 210000003491 skin Anatomy 0.000 description 23
- 229920002385 Sodium hyaluronate Polymers 0.000 description 22
- 229940010747 sodium hyaluronate Drugs 0.000 description 22
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 22
- 239000000047 product Substances 0.000 description 18
- 238000004132 cross linking Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 13
- 239000003431 cross linking reagent Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 8
- 239000012535 impurity Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- 230000037365 barrier function of the epidermis Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000037394 skin elasticity Effects 0.000 description 4
- 230000003796 beauty Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940116978 human epidermal growth factor Drugs 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- -1 carboxymethyl hyaluronic acid Chemical compound 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 238000000694 mesotherapy Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2405/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2401/00 or C08J2403/00
- C08J2405/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Definitions
- the present invention relates to the field of biomedicine, in particular to a hyaluronic acid gel composition for water-light injection, and also relates to a preparation method of the hyaluronic acid gel composition for water-light injection.
- Water and light injection is currently one of the most extensive medical beauty projects at home and abroad. It can effectively solve the problem of skin care products that are not easily absorbed through the epidermal barrier. It can quickly and effectively replenish the skin, thereby effectively improving skin quality and delaying senescence.
- Water-light injection originated from Mesotherapy proposed by French doctor Michal Pistor in 1952. The idea is to inject a small amount of therapeutic substance into the local superficial surface. After decades of hard work, the current water-light acupuncture technology was developed.
- Water-light injection uses negative pressure technology to accurately pierce several extremely thin needles into the skin about 1 to 2 mm, and directly transport the repairing substance through the epidermal layer into the epidermis and the dermis or the dermis layer, which solves the effective ingredients in skin care products.
- Hyaluronic acid also known as hyaluronic acid, is an acidic mucopolysaccharide inherent in the human body. It is widely used in various skin care products. It is a super moisturizing agent naturally present in human skin and can maintain moisture 1,000 times its own weight. The moisture level of the skin is closely related to the content and molecular weight of hyaluronic acid. High molecular weight hyaluronic acid has stronger water retention properties. With the increase of age and the destruction of daily active oxygen free radicals, the endogenous hyaluronic acid in the skin is continuously degraded and lost, and the water retention function is gradually weakened, which leads to various skin aging symptoms, such as dryness, roughness, and dullness. , Relaxation, wrinkles, etc. (Stern et al. Clinics in Dermatology 2008, 26: 106-122; Papakonstantinou et al., Dermatoendocrinol 2012, 4: 253-258).
- Supplementing exogenous hyaluronic acid is an important measure to improve skin texture, delay aging symptoms and restore youthfulness.
- the hyaluronic acid applied on the skin surface is difficult to be effectively absorbed, especially the high molecular weight hyaluronic acid with super moisturizing ability.
- Water-light injection of hyaluronic acid can directly penetrate the epidermal barrier, and can immediately replenish hyaluronic acid in the superficial layer of the skin to achieve the effect of rapid moisturizing and moisturizing and achieve the ultimate goal of improving skin quality.
- water-light injection is mainly superficial injection to supplement exogenous hyaluronic acid, and it also contains other restorative nutrients as appropriate.
- CN 106074213A discloses a hyaluronic acid gel for water and light injection, which consists of 10-30 parts of sodium hyaluronate, 0.5-3 parts of glycerin, 0.5-1.5 parts of mannitol, and 1-9 parts of mannitol. The pH adjuster and 25 to 45 parts of isotonic adjuster.
- CN 105233270A discloses a pharmaceutical composition for water-light therapy and its application.
- composition includes: 0.01-0.5wt% high molecular weight sodium hyaluronate, 0.01-0.3wt% medium molecular weight sodium hyaluronate, 0.01-1wt% % Low molecular weight sodium hyaluronate, 0.01-1wt% oligomeric sodium hyaluronate, 0.01-5wt% collagen, 0.05-1.8wt% adjuvant, recombinant human epidermal growth factor, the balance is water, reconstituted
- concentration of human epidermal growth factor is 0.5-10 ⁇ g/ml; the molecular weight of high molecular weight sodium hyaluronate is 1.3-2 million daltons, the molecular weight of medium molecular weight sodium hyaluronate is 500,000-1 million daltons, and the low molecular weight is transparent
- the molecular weight of sodium phosphate is 50,000 to 300,000 daltons, and the molecular weight of oligomeric sodium hyaluronate is
- hyaluronic acid is rapidly degraded into small molecular fragments and enters the body fluid circulation to be absorbed and metabolized, and loses the function of moisturizing and moisturizing in the skin; in the skin, the half-life of hyaluronic acid is less than 1 Tian (Laurent et al., Exp Physiol 1991, 76: 695-703). Therefore, although water injection can quickly replenish hyaluronic acid in the skin, it can only moisturize and moisturize in a short time, and it is difficult to achieve long-term effects such as improving skin texture, delaying aging and restoring youthfulness. For example, the research results of Amin et al.
- Cross-linking modification can delay the degradation and absorption of hyaluronic acid in the body, such as 1,4-butanediol diglycidyl ether (BDDE) cross-linked hyaluronic acid gel (such as Rui Lan Etc.)
- BDDE 1,4-butanediol diglycidyl ether
- the degradation and absorption time under the skin can be as long as 6 months, and it is widely used for wrinkle injection and filling.
- cross-linked hyaluronic acid gel products are very high (usually not less than 20mg/mL) (Edsman et al., Dermatol Surg 2012, 38:1170-1179), that is, the water content is usually not more than 98% (cross-linked The water content of hyaluronic acid is about 49 times of its own weight), and its moisturizing and moisturizing properties are poor; in addition, these cross-linked hyaluronic acid gel products also have greater gel strength and need to be crushed into particles before they can be used.
- the cross-linked hyaluronic acid gel in the prior art has a long degradation time, it is not suitable for water-light injection and has a slow onset; the technical problem that hyaluronic acid used for water-light injection has a short maintenance time in the body is prolonged The water retention time of hyaluronic acid injection by water light needle and the accelerated onset time.
- the present application provides a hyaluronic acid gel composition for water light injection, which has longer degradation and absorption time than existing hyaluronic acid, and is more effective. Long hydration and moisturizing maintenance time and faster onset time. It is also suitable for water-light injection. It has low impurity toxicity and does not cause bulging. Therefore, water-light injection can more effectively improve the skin texture.
- a hyaluronic acid gel composition for water-light injection containing:
- Disulfide bond cross-linked hyaluronic acid, and its content is not more than 10mg/mL;
- Water-light injection is usually carried out by local spot injection, supplementing the superficial layer of each injection point with nourishing substances such as hyaluronic acid.
- nourishing substances such as hyaluronic acid.
- the nourishing substance needs to have a certain fluidity, which can quickly diffuse to the non-injection point, so as to play a role of moisturizing and moisturizing on the entire skin (such as the face).
- the hyaluronic acid gel composition for water light injection includes non-crosslinked hyaluronic acid.
- Non-cross-linked hyaluronic acid has good flow and dispersibility. It has a quick effect after water injection and can play a role of rapid hydration and moisturizing. Its disadvantages are that the degradation and absorption are too fast, and the duration of moisturizing and moisturizing is short, which is difficult to satisfy water. The need for moisturizing and maintaining time in light needle application.
- the hyaluronic acid gel composition for water light injection according to the present invention also includes disulfide bond cross-linked hyaluronic acid, and its content is not more than 10 mg/ml.
- hyaluronic acid is cross-linked, due to the greater gel strength, higher hyaluronic acid content, and poor flow and dispersion, it is often limited to the injection site and cannot be used for water-light injection.
- the cross-linked hyaluronic acid has a slow onset of effect, and even completely fails to meet the requirements of water injection. Therefore, the cross-linked hyaluronic acid gel needs to be specially optimized for water-light injection.
- the disulfide bond cross-linked hyaluronic acid contained in the composition according to the present invention has a content of not more than 10 mg/mL in the gel, has good biocompatibility and stability, and can realize effective disulfide bond cross-linking Link, delay the metabolism and absorption in the body. It is used to prepare the hyaluronic acid gel composition for water and light injection without adding a cross-linking agent, the preparation process is simple, does not contain impurities, and can avoid the current complex process and cross-linking agent for cross-linking hyaluronic acid gel products Toxic side effects caused by residues.
- the hyaluronic acid sulfhydryl derivative disclosed in the applicant's prior art patent document CN 102399295A can be used to prepare the disulfide bond cross-linked hyaluronic acid for water-light injection of the present invention.
- the use of the disulfide bond cross-linked hyaluronic acid for water-light injection has many advantages, such as easy water-light injection, uniform distribution in the superficial subcutaneous layer, no bulging phenomenon, and the maintenance time of moisturizing and moisturizing effect is significantly better than that of the previous Cross-linked hyaluronic acid, etc.
- the hyaluronic acid gel composition provided by the present invention contains both the above-mentioned disulfide bond cross-linked hyaluronic acid gel and non-cross-linked hyaluronic acid, and has the advantages of both when used for water-light injection.
- the above-mentioned problems existing in the prior art are better solved. It not only meets the requirement of flow dispersion, but also prolongs the water retention time and speeds up the effect.
- the content of the disulfide cross-linked hyaluronic acid is expressed as the weight (mg/mL) of the disulfide cross-linked hyaluronic acid contained in the unit volume of the hyaluronic acid gel composition.
- the content of disulfide cross-linked hyaluronic acid in the hyaluronic acid gel composition for water-light injection of the present invention is not more than 10 mg/mL, preferably 1 to 4 mg/mL, particularly preferably 2 to 3 mg/mL .
- the content of disulfide cross-linked hyaluronic acid in the hyaluronic acid gel composition for water injection of the present invention is low .
- the hyaluronic acid gel composition for water injection of the present invention has lower strength, better fluidity, and is easier to pass
- the ultra-fine needle of the water light needle is used for injection and achieves uniform distribution in the superficial layer of the skin.
- the content of the non-crosslinked hyaluronic acid is expressed as the weight (mg/mL) of the non-crosslinked hyaluronic acid contained in the unit volume of the hyaluronic acid gel composition.
- the content of non-cross-linked hyaluronic acid in the hyaluronic acid gel composition for water-light injection of the present invention is usually not more than 10 mg/mL, preferably between 1 and 5 mg/mL, particularly preferably 2 ⁇ 4mg/mL.
- the molecular weight refers to the average molecular weight.
- Cross-linked hyaluronic acid has no concept of molecular weight due to its cross-linked structure.
- the molecular weight distribution of non-crosslinked hyaluronic acid is very wide, and different molecular weights have different physical, chemical and biological properties.
- high molecular weight hyaluronic acid with a molecular weight greater than 800kDa (800,000 daltons) usually has good moisturizing and moisturizing properties.
- the molecular hyaluronic acid (an oligosaccharide with 6-20 disaccharide repeating units, that is, the molecular weight is 2.4KDa ⁇ 8KDa) can slightly improve blood supply (promote micro-angiogenesis), promote fibroblast growth and endogenous macromolecule transparency
- the secretion and synthesis of plasmic acid (Smejkalova et al., Harry's Cosmeticology 9th Edition Vol.2.Part 4.1.3, pp.605-622; Publisher: Chemical Publishing Company, 2015).
- the non-crosslinked hyaluronic acid may have a molecular weight, and its molecular weight is usually between 1KDa and 10,000KDa, preferably between 800KDa and 3,000KDa, particularly preferably between 1,000KDa ⁇ 2,800Kda.
- the non-crosslinked hyaluronic acid may also include two or more different molecular weights, preferably at least one of the non-crosslinked hyaluronic acid has a molecular weight of 1.6KDa
- the molecular weight of at least one non-crosslinked hyaluronic acid is between 800KDa and 3,000KDa. It is particularly preferred that the molecular weight of at least one non-crosslinked hyaluronic acid is between 2.4 and 8KDa.
- a non-crosslinked hyaluronic acid has a molecular weight between 1,000KDa and 2,800KDa.
- the hyaluronic acid can be in the form of its salt (such as sodium salt, potassium salt, zinc salt, calcium salt, etc.), or it can include a non-crosslinked structure obtained by chemical modification.
- its salt such as sodium salt, potassium salt, zinc salt, calcium salt, etc.
- Derivatives such as carboxymethyl hyaluronic acid, acetylated hyaluronic acid, etc.
- a method similar to that disclosed in the prior art (CN 101721349A) of the applicant of the present invention can be used to prepare the disulfide bond cross-linked hyaluronic acid of the present invention.
- the preparation method realizes disulfide bond cross-linking by the hyaluronic acid sulfhydryl derivative aqueous solution under the oxidation of oxygen (oxygen in the air and/or dissolved oxygen in the aqueous solution), without the need to add a cross-linking agent, and the by-products are Water has many advantages such as simple production process and no impurities, which avoids the current complicated process of cross-linking hyaluronic acid gel products and the potential toxic and side effects caused by the residual cross-linking agent.
- the above-mentioned preparation method of disulfide cross-linked hyaluronic acid does not require a purification process, and is particularly suitable for preparing cross-linked gels with low strength and certain fluidity, and is suitable for water Light injection purposes.
- the hyaluronic acid sulfhydryl derivatives refer to hyaluronic acid derivatives containing sulfhydryl groups, which can be prepared by sulfhydryl modification of hyaluronic acid, and also include various hyaluronic acid derivatives further through sulfhydryl groups.
- the sulfhydryl derivative prepared by chemical modification.
- the side chain carboxyl groups, side chain hydroxyl groups, and reducing end groups of hyaluronic acid or its salts or derivatives are usually reactive functional groups that can be modified by sulfhydrylization, as disclosed in previous documents such as WO 2009/006780A1.
- hyaluronic acid sulfhydryl derivatives can be used to prepare the hyaluronic acid sulfhydryl derivatives of the present invention; these hyaluronic acid sulfhydryl derivatives better maintain the initial structure, physiological functions and biological functions of hyaluronic acid. Compatibility, and can achieve effective disulfide bond cross-linking, significantly delaying the metabolism and absorption in the body.
- sulfhydryl derivatives of hyaluronic acid with various sulfhydryl content can be used to prepare the disulfide cross-linked hyaluronic acid of the present invention.
- the sulfhydryl content is expressed as the number of micromoles of sulfhydryl groups per gram of hyaluronic acid sulfhydryl derivatives ( ⁇ mol/g).
- the sulfhydryl content of the hyaluronic acid sulfhydryl derivatives used in the present invention is usually between 10 and 100 ⁇ mol/g.
- the preferred mercapto group content is between 10-50 ⁇ mol/g, and the particularly preferred mercapto group content is between 20-40 ⁇ mol/g.
- Another object of the present invention is to provide a method for preparing the hyaluronic acid gel composition for water-light injection.
- a technical solution of the preparation method is: the sulfhydryl derivative of hyaluronic acid is dissolved to obtain an aqueous solution, and the disulfide bond cross-linked hyaluronic acid gel is obtained through an oxidation process, and then it is physically mixed with the aqueous solution of hyaluronic acid, namely The hyaluronic acid gel composition for water-light injection of the present invention can be obtained.
- the above-mentioned oxidation process can usually be carried out under the action of oxygen, such as oxygen in the air and/or dissolved oxygen in an aqueous solution.
- oxygen such as oxygen in the air and/or dissolved oxygen in an aqueous solution.
- physical mixing process can adopt methods well known to those skilled in the art, such as mechanical stirring and mixing.
- the preparation method realizes the disulfide bond cross-linked gel under the oxidation of the hyaluronic acid sulfhydryl derivative aqueous solution under oxygen (oxygen in the air and/or dissolved oxygen in the aqueous solution), and does not require the addition of a cross-linking agent.
- the product is water, the production process is simple, and it does not contain impurities. It avoids the current complicated process of cross-linking hyaluronic acid gel products and the potential toxic side effects caused by cross-linking agent residues.
- the water injection treatment is obtained by simple mixing. Hyaluronic acid gel composition.
- the aqueous solution of hyaluronic acid thiolated derivative and the aqueous solution of hyaluronic acid can be filtered and sterilized, and then the hyaluronic acid gel for water-light injection of the present invention can be prepared under aseptic conditions.
- the glue composition can also adopt terminal sterilization and other methods, and the terminal sterilization method can adopt methods such as moist heat sterilization well known to those skilled in the art.
- Another technical solution of the preparation method is: the aqueous solution of hyaluronic acid thiolated derivative and the aqueous solution of hyaluronic acid are physically mixed to obtain a mixed solution, and then the disulfide bond cross-linking is formed through the oxidation process, that is, the method of the present invention is obtained.
- Hyaluronic acid gel composition for water injection The oxidation process can also be carried out under the action of oxygen, such as oxygen in the air and/or dissolved oxygen in an aqueous solution.
- the preparation method obtains a mixture of hyaluronic acid by simple mixing, and the aqueous solution of hyaluronic acid sulfhydryl derivative realizes disulfide bond cross-linking under the oxidation of oxygen (oxygen in the air and/or dissolved oxygen in the aqueous solution).
- the by-product is water, the production process is simple and contains no impurities, etc., which avoids the current complex process of cross-linking hyaluronic acid gel products and the potential toxic side effects caused by cross-linking agent residues, and obtains hyaluronic acid Acid gel composition.
- the preparation process can also adopt an aseptic process, or terminally sterilize the prepared hyaluronic acid gel composition.
- the non-cross-linked hyaluronic acid or its derivatives are physically embedded in the disulfide cross-linked hyaluronic acid, forming a semi-interconnected hyaluronic acid well known to those skilled in the art. Wear the structure of the network.
- the hyaluronic acid gel composition for water-light injection may also contain a variety of nutritionally active substances, such as various vitamins, amino acids, growth factors, etc., to achieve synergistic water-light injection replenishment Moisturizing and other effects.
- the nutrient active substance can be dissolved in an aqueous solution of hyaluronic acid thiolated derivative and/or an aqueous solution of hyaluronic acid, and then a hyaluronic acid gel composition containing nutrients can be prepared according to the above two preparation methods.
- the dendritic acid gel composition for water-light injection of the present invention contains both disulfide bond cross-linked hyaluronic acid and non-cross-linked hyaluronic acid, has good fluidity, and is easy to pass through the water-light needle. Injection with a fine needle can achieve a good uniform distribution in the superficial subcutaneous layer without bulging, and the advantages of fast moisturizing and long-lasting effect after water-light injection can effectively improve the skin texture.
- the hyaluronic acid gel composition for water-light injection has the advantages of disulfide cross-linked hyaluronic acid and non-cross-linked hyaluronic acid when used for water-light injection, and effectively solves the problem of non-cross-linked hyaluronic acid.
- Cross-linked hyaluronic acid has a fast onset of action but has a short duration of moisturizing and moisturizing
- disulfide cross-linked hyaluronic acid has a long time of moisturizing and moisturizing but the onset time is delayed.
- the dendritic acid gel composition for water and light injection of the present invention can be conveniently prepared by hyaluronic acid sulfhydryl derivative aqueous solution and non-crosslinked hyaluronic acid aqueous solution.
- Many advantages such as simple process, no impurities, easy addition of other nutritional active substances, etc., avoid the current complicated process of cross-linking hyaluronic acid gel products and the toxic side effects caused by the residual cross-linking agent.
- the disulfide bond crosslinking is realized by the hyaluronic acid sulfhydryl derivative aqueous solution under the oxidation of oxygen (oxygen in the air and/or dissolved oxygen in the aqueous solution), and there is no need to add a crosslinking agent,
- the by-product is water, the production process is simple, and there are many advantages such as no impurities, which avoids the current complicated process of cross-linking hyaluronic acid gel products and the potential toxic side effects caused by cross-linking agent residue; the hyaluronic acid of the present invention is obtained by simple mixing Acid gel mixture.
- Figure 2 The effect of sodium hyaluronate gel composition on skin elasticity after water injection.
- Figure 3 The effect of sodium hyaluronate gel composition on the depth of skin wrinkles after water and light injection.
- Hyaluronic acid sulfhydryl derivatives are prepared from sodium hyaluronate with a molecular weight of 180KDa as a raw material and prepared by the method reported by Shu et al. (Shu et al., Biomacromolecules 2002, 3:1304-1311). The sulfhydryl content is 24 ⁇ mol/g and 38 ⁇ mol, respectively. /g and 57 ⁇ mol/g.
- Sodium hyaluronate (50KDa) was dissolved to obtain an aqueous solution with a content of 12 mg/mL, the pH of the solution was adjusted to 7.4, and the solution was sterilized and filtered for later use.
- Example 3 Evaluation of the injectable properties of the hyaluronic acid gel composition
- Adopt Derma (Demasha) 2nd generation water-light injection device test the injectability of the hyaluronic acid gel composition prepared in Example 2 through conventional water-light injection needles (nine needles).
- the content of disulfide cross-linked hyaluronic acid in the hyaluronic acid gel composition is 1mg/mL, 2mg/mL, 3mg/mL and 4mg/mL, it has good injectability; and when the content is ⁇ 5mg/mL When it is mL, it is difficult to inject through the water light injection instrument.
- Example 4 Evaluation of the injectable properties of the diluted hyaluronic acid gel composition
- the hyaluronic acid gel composition prepared in Example 2 (disulfide cross-linked hyaluronic acid content is: 5mg/mL, 8mg/mL, 9mg/mL, 10mg/mL and 11mg/mL) and physiological saline According to the volume ratio of 1:2 for physical mixing and dilution.
- the dilution process is carried out in a syringe connected by a two-way connector.
- One syringe contains the hyaluronic acid gel composition (1 mL) prepared in Example 2, and the other syringe contains 2 mL of normal saline.
- Perform physical dilution and mixing 80 times. Two-way joints with a smaller diameter (such as less than 1mm) can be used to achieve better dilution and mixing effects.
- Adopt Derma (Demasha) 2nd generation water-light injection instrument test the injectability of the diluted hyaluronic acid gel composition through conventional water-light injection needles (nine needles). The test results show that each diluted hyaluronic acid gel composition has good injectability.
- Sodium hyaluronate is dissolved to obtain an aqueous solution with a content of 2mg/mL, 4mg/mL, 6mg/mL, 8mg/mL or 10mg/mL, the pH of the solution is adjusted to 7.4, and it is ready for use after sterilization and filtration.
- the molecular weight of the sodium hyaluronate used is 1.6KDa, 3KDa, 8KDa, 50KDa, 180KDa, 500KDa, 800KDa, 1,500KDa or 2,700KDa. It can be any of these molecular weights, or any two or more of them. The molecular weight is combined in any weight ratio.
- the disulfide cross-linked hyaluronic acid gel (6 mg/mL) prepared in Example 1 was physically stirred and mixed with the above-mentioned hyaluronic acid aqueous solution at a volume ratio of 1:1 to obtain a hyaluronic acid gel composition.
- the content of sulfur-bonded cross-linked hyaluronic acid is 3 mg/mL, and the content of hyaluronic acid is 1 mg/mL, 2 mg/mL, 3 mg/mL, 4 mg/mL, or 5 mg/mL.
- Example 6 Evaluation of the injectable properties of the hyaluronic acid gel composition
- Adopt Derma (Demasa) 2nd generation water-light injection device to test the injectability of the hyaluronic acid gel composition prepared in Example 5 through conventional water-light injection needles (nine needles). The test results show that each gel composition has good injectability.
- Hyaluronic acid sulfhydryl derivatives are prepared using sodium hyaluronate with molecular weights of 300KDa and 1,500KDa as raw materials, prepared by the method reported by Shu et al. (Shu et al., Biomacromolecules 2002, 3:1304-1311), and their sulfhydryl content is 33 ⁇ mol/ g and 40 ⁇ mol/g.
- hyaluronic acid sulfhydryl derivative and sodium hyaluronate are jointly dissolved to obtain a mixed aqueous solution, wherein the content of hyaluronic acid sulfhydryl derivative is 2.5 mg/mL or 5 mg/mL, and the content of sodium hyaluronate is 1 mg/mL, respectively.
- the molecular weight of the sodium hyaluronate used is 1.6KDa, 3KDa, 8KDa, 50KDa, 180KDa, 500KDa, 800KDa, 1,500KDa or 2,700KDa. It can be any one of these molecular weights, or any two or two of them. According to the combination of any weight ratio.
- Example 8 Evaluation of the injectable properties of the hyaluronic acid gel composition
- Adopt Derma (Demasha) 2nd generation water-light injection device test the injectability of the hyaluronic acid gel composition prepared in Example 7 through conventional water-light injection needles (nine needles). The test results show that each gel composition has good injectability.
- Example 9 Water absorption and water retention performance of hyaluronic acid gel composition
- Example 7 Using the same dilution process as in Example 4, the gel prepared in Example 7 and physiological saline were physically mixed and diluted according to a volume ratio of 1:2, and then put into a small glass bottle and left at room temperature for 1 hour. None was observed. Obvious delamination between the water phase and the gel phase indicates that the gel has good water absorption and water retention properties.
- Example 10 Evaluation of hydro-light injection effect of hyaluronic acid gel composition
- Samples used in the test group the gel composition prepared in Example 5, the content of disulfide cross-linked hyaluronic acid was 3 mg/mL (prepared with 38 ⁇ mol/g sulfhydryl derivatives), non-cross-linked sodium hyaluronate The content of 2mg/mL (1,500KDa).
- the sample used in the control group I 5 mg/mL non-crosslinked sodium hyaluronate aqueous solution (molecular weight 1.5MDa).
- the sample used in the control group II the same sample used in the test group, but does not contain non-crosslinked sodium hyaluronate.
- the relative increase in skin moisture before and after injection (%) was tested with a skin moisture meter, the relative increase in skin elasticity (%) before and after injection was tested with a skin elasticity meter, and the relative decrease in average wrinkle depth before and after injection was tested with a fast three-dimensional imaging system Evaluation.
- test results of this embodiment are shown in Figures 1-3.
- the cross-linked hyaluronic acid gel composition has a better hydro-light treatment effect, quick onset and long maintenance time; at the same time, all test subjects in the test group have no bulging phenomenon, which indicates The cross-linked hyaluronic acid gel composition has good fluidity and can be evenly distributed on the superficial layer of water injection.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dispersion Chemistry (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种用于水光注射的透明质酸凝胶组合物，含有1)二硫键交联透明质酸，且透明质酸在凝胶中的含量不大于10mg/mL；和2)非交联的透明质酸。该透明质酸凝胶组合物用于水光注射时具有独特的优势，易于通过水光针极细针头进行注射，可在皮下浅表层实现良好的均匀分布，不会出现鼓包现象；起效快且补水保湿效果维持时间长，可有效改善肌肤肤质。
Description
本发明涉及生物医药领域，特别涉及一种用于水光注射的透明质酸凝胶组合物，还涉及所述用于水光注射的透明质酸凝胶组合物的制备方法。
近年来国内外医疗美容行业发展迅速，研发了各类新兴美容技术。水光注射是当前国内外开展最为广泛的医疗美容项目之一，能有效解决体表使用护肤品不易透过表皮屏障吸收的问题，可快速有效给予肌肤补水补养，因而可有效改善肤质及延缓衰老。水光注射源于法国医生Michal Pistor于1952年提出的中胚层疗法(Mesotherapy)，其理念是在局部浅表注射微量治疗物质；之后经过几十年的努力开发出了当前的水光针技术。水光注射通过负压技术将数个极细的针头精确刺入皮下约1～2毫米处，透过表皮层直接将修复物质输送入表皮和真皮之间或真皮层，解决了护肤品中有效成分无法有效穿透表皮屏障的问题。
透明质酸又名玻尿酸，是一种人体内固有的酸性黏多糖，被普遍应用于各种护肤品，是人体肌肤中天然存在的超强保湿剂，可维持自身重量1000倍的水份。肌肤的湿润水平与透明质酸含量及分子量密切相关，高分子量的透明质酸具有更强的保水性能。随着年龄的增长以及日常活性氧自由基的破环作用，肌肤中内源性透明质酸不断被降解流失，保水功能逐渐弱化，因而导致了各种肌肤衰老症状，如干燥、粗糙、暗沉、松弛、皱纹等等(Stern等，Clinics in Dermatology 2008,26:106-122；Papakonstantinou等，Dermatoendocrinol 2012,4:253-258)。
补充外源性透明质酸是改善肌肤肤质、延缓衰老症状及恢复年轻态的重要措施。然而由于表皮屏障的存在，涂抹在肌肤表面的透明质酸很难被有效吸收，特别是具有超强保湿能力的高分子量透明质酸。水光注射透明质酸可直接透过表皮屏障，可即刻在肌肤浅表层补充透明质酸，以实现快速补水保湿的功效及达到改善肤质的终极目的。当前水光注射以浅表注射补充外源性透明质酸为主，同时也适当含有其它修复营养物质。CN 106074213A公开了一种用于水光注射的透明质酸凝胶，其组成包括10～30份的透明质酸钠、0.5～3份的甘油、0.5～1.5份的甘露醇、1～9份的pH调节剂和25～45份的等渗调节剂。CN 105233270A公开了用于水光治疗的药物组合物及其应用，其组成包括：0.01～0.5wt％的高分子量透明质酸钠、0.01～0.3wt％的中分子量透明质酸钠、0.01～1wt％的低分子量透明质酸钠、0.01～1wt％的寡聚透明质酸钠、0.01～5wt％的胶原蛋白、0.05～1.8wt％的辅剂、重组人表皮生长因子，余量为水，重组人表皮 生长因子的浓度为0.5～10μg/ml；高分子量透明质酸钠的分子量为130～200万道尔顿，中分子量透明质酸钠的分子量为50～100万道尔顿，低分子量透明质酸钠的分子量为5～30万道尔顿，寡聚透明质酸钠的分子量为3000～8000道尔顿。
然而，透明质酸在体内透明质酸酶的作用下，被快速降解成小分子片段进入体液循环被吸收代谢，失去了在肌肤局部补水保湿的功能；在皮肤中，透明质酸的半衰期小于1天(Laurent等，Exp Physiol 1991,76:695-703)。因此，水光注射虽然可在肌肤局部快速补充透明质酸，但只能在短时间内起到补水保湿，难以实现改善肤质、延缓衰老及恢复年轻态等较长期效果。例如，Amin等(Dermatol Surg 2006,32:1467-1472)和El-Domyati等(International Journal of Dermatology 2012,51:913-919)的研究结果均表明透明质酸水光注射的疗效有待进一步提高。
交联改性可延缓透明质酸在体内的降解吸收，例如1,4-丁二醇二缩水甘油醚(BDDE)交联透明质酸凝胶(如瑞蓝
等)在皮下的降解吸收时间可长达6个月以上，被广泛用于皱纹注射填充。然而，当前交联透明质酸凝胶产品的含量很高(通常不小于20mg/mL)(Edsman等，Dermatol Surg 2012,38:1170-1179)，亦即含水量通常不大于98％(交联透明质酸自身重量约49倍的含水量)，补水保湿性能较差；并且，该等交联透明质酸凝胶产品还具有较大的凝胶强度，需粉碎为颗粒状后才能使用，且推挤力较大，很难通过水光针极细针头进行浅表层注射；此外，该等交联透明质酸凝胶产品的流动性差，无法在水光注射的浅表层均匀分布，容易形成鼓包且在短期内无法降解消除。因此，当前交联透明质酸凝胶产品用于水光注射用途存在诸多局限性。
发明内容
为了解决现有技术中交联透明质酸凝胶虽然降解时间长，但是不适合于水光注射，而且起效慢；用于水光注射的透明质酸在体内维持时间短的技术问题，延长水光针注射透明质酸的保水时间以及加快起效时间，本申请提供了一种用于水光注射的透明质酸凝胶组合物，比现有透明质酸更长的降解吸收时间、更长的补水保湿维持时间和更快的起效时间，同时适合于水光注射用途，杂质毒性小，且不会产生鼓包现象，因而可以通过水光注射更有效地改善肌肤肤质。
本发明通过以下技术方案实现：
一种用于水光注射的透明质酸凝胶组合物，含有：
1)二硫键交联透明质酸，且其含量不大于10mg/mL；和
2)非交联的透明质酸。
水光注射通常采用局部点状注射方式进行，在各注射点浅表层补充透明质酸等补养物质。然而注射点之间存在相当的间距，因此要求补养物质需要有一定的流动性，能够迅速弥漫至非注射点部位，从而在整个肌肤(如面部)起到补水保湿的作用。
根据本发明的用于水光注射透明质酸凝胶组合物包括非交联的透明质酸。非交联的透明质酸具有较好的流动弥散性，水光注射后起效快，可起到快速补水保湿的作用，其缺点是降解吸收过快，补水保湿持续时间较短，难以满足水光针应用中补水保湿维持时间的需要。
根据本发明的用于水光注射透明质酸凝胶组合物还包括二硫键交联的透明质酸，且其含量不大于10mg/ml。
通常透明质酸被交联后，由于较大的凝胶强度，较高的透明质酸含量、且流动弥散性较差，经常局限在注射点部位，无法用于水光注射。而且交联的透明质酸起效慢，甚至完全达不到水光注射的要求。因此交联的透明质酸凝胶用于水光注射需要特别优化设计。
根据本发明的组合物所包含的二硫键交联透明质酸，其在凝胶中的含量不大于10mg/mL，具有良好的生物相容性和稳定性，可实现有效的二硫键交联，延缓体内代谢吸收。将其用于制备用于水光注射透明质酸凝胶组合物不需要添加交联剂，制备工艺简单、不含杂质，可避免当前交联透明质酸凝胶产品的复杂工艺及交联剂残余引起的毒副作用。可采用本发明申请人在先技术专利文献CN 102399295A所公开的透明质酸巯基化衍生物来制备本发明所述用于水光注射的二硫键交联透明质酸。将所述二硫键交联透明质酸用于水光注射具有很多优点，如易于水光注射、可在皮下浅表层均匀分布、不会出现鼓包现象，且补水保湿效果维持时间显著优于未交联透明质酸等。
本发明所提供的透明质酸凝胶组合物，同时含有上述二硫键交联透明质酸凝胶和非交联透明质酸，用于水光注射时同时兼具了两者的的优点，较好解决了现有技术中存在的上述问题。既满足了流动弥散性要求，又延长了保水时间，加快了起效速度。
在本发明中，所述的二硫键交联透明质酸的含量表示为透明质酸凝胶组合物单位体积中含有的二硫键交联透明质酸的重量(mg/mL)。本发明所述的用于水光注射的透明质酸凝胶组合物中的二硫键交联透明质酸的含量不大于10mg/mL，优选1～4mg/mL，特别优选2～3mg/mL。
与交联透明质酸产品的含量(通常不小于20mg/mL)相比较，本发明所述用于水光注射的透明质酸凝胶组合物中的二硫键交联透明质酸的含量低，通常仅为当前交联透明质酸产品的50％以下；因此，本发明所述用于水光注射的透明质酸凝胶组合物的强度更低，具有更好的流动性，更易于通过水光针极细针头进行注射及实现在皮下浅表层的均匀分布。
在本发明中，所述的非交联的透明质酸的含量表示为透明质酸凝胶组合物单位体积中含有的非交联的透明质酸的重量(mg/mL)。本发明所述的用于水光注射的透明质酸凝胶组合物中的非交联的透明质酸的含量通常不大于10mg/mL，优选在1～5mg/mL之间，特别优选在2～4mg/mL之间。
在本发明中，所述的分子量是指平均分子量。交联透明质酸由于其交联结构，因而不存在分子量的概念。非交联的透明质酸的分子量分布很广泛，不同分子量具有不同的理化和生物性能，例如分子量大于800kDa(80万道尔顿)的高分子量透明质酸通常具有良好的补水保湿性能，而小分子透明质酸(6～20个二糖重复单元的寡糖，亦即分子量为2.4KDa～8KDa)可轻微改善血运(促进微小血管生成)、促进成纤细胞生长及内源性大分子透明质酸的分泌合成(Smejkalova等，Harry’s Cosmeticology 9th Edition Vol.2.Part 4.1.3,pp.605-622；Publisher:Chemical Publishing Company,2015)。
在本发明的一个实施例中，所述的非交联的透明质酸可以是一种分子量，其分子量通常在1KDa～10,000KDa之间，优选在800KDa～3,000KDa之间，特别优选在1,000KDa～2,800Kda之间。
在本发明的另一个实施例中，所述的非交联的透明质酸也可以包括两种及两种以上不同的分子量，优选其中至少一种非交联的透明质酸的分子量在1.6KDa～500KDa之间且其中至少一种非交联的透明质酸的分子量在800KDa～3,000KDa之间，特别优选其中至少一种非交联的透明质酸的分子量在2.4～8KDa之间且其中至少一种非交联的透明质酸的分子量在1,000KDa～2,800KDa之间。
在本发明中，所述的透明质酸可以是其盐的形式(如钠盐、钾盐、锌盐、钙盐等)，也可以是包括其经过化学改性所得到的非交联结构的衍生物，如羧甲基透明质酸、乙酰化透明质酸等。
在本发明中，可采用类似于本发明申请人在先技术(CN 101721349A)所公开的方法来制备本发明所述的二硫键交联透明质酸。该制备方法通过透明质酸巯基化衍生物水溶液在氧气(空气中的氧气和/或水溶液中的溶解氧)的氧化作用下实现二硫键交联，具有不需要添加交联剂，副产物为水，生产工艺简单以及不含杂质等许多优点，避免了当前交联透明质酸凝胶产品的复杂工艺及交联剂残余引起的潜在毒副作用。
如本领域技术人员所熟知，在当前的交联透明质酸凝胶产品的制备工艺中，常规采用浸泡透析方式进行纯化，亦即通过将交联反应后的凝胶浸泡于大量的水或缓冲盐溶液中，以透析除去交联凝胶中残余的交联剂等杂质；该纯化过程要求交联凝胶具有较高的强度，因此当 前交联透明质酸凝胶产品均具有较高的强度，不适合于水光注射用途。与此相反，在本发明中，所述的二硫键交联透明质酸的上述制备方法不需要纯化过程，特别合适于制备强度较低、具有一定流动性的交联凝胶，适合于水光注射用途。
在本发明中，所述的透明质酸巯基化衍生物是指含有巯基的透明质酸衍生物，可通过透明质酸的巯基化改性制备，也包括各种透明质酸衍生物进一步通过巯基化改性所制备的巯基化衍生物。透明质酸或其盐或其衍生物的侧链羧基、侧链羟基、以及还原性端基等通常是可进行巯基化改性的活性官能团，WO 2009/006780A1等在先文件所公开的多种透明质酸巯基化衍生物制备方法均可用于制备本发明所述的透明质酸巯基化衍生物；该等透明质酸巯基化衍生物较好保持了透明质酸的初始结构、生理功能和生物相容性，且可实现有效的二硫键交联，显著延缓体内的代谢吸收。
在本发明中，各种巯基含量的透明质酸巯基化衍生物均可用于制备本发明所述的二硫键交联透明质酸。巯基含量表示为每克透明质酸巯基化衍生物中含有的巯基的微摩尔数(μmol/g)，本发明所采用的透明质酸巯基化衍生物的巯基含量通常在10～100μmol/g之间，优选的巯基含量在10～50μmol/g之间，特别优选的巯基含量在20～40μmol/g之间。
本发明的再一个目的是提供所述的用于水光注射的透明质酸凝胶组合物的制备方法。
所述制备方法的一种技术方案是：透明质酸巯基化衍生物溶解得到水溶液，并经氧化过程得到二硫键交联透明质酸凝胶，然后与透明质酸的水溶液进行物理混合，即可得到本发明所述的用于水光注射的透明质酸凝胶组合物。
上述的氧化过程通常可在氧气的作用进行，如空气中的氧气和/或水溶液中的溶解氧。上述的物理混合过程可采用本领域技术人员所熟知的方式，如机械搅拌混合等。
本制备方法通过透明质酸巯基化衍生物水溶液在氧气(空气中的氧气和/或水溶液中的溶解氧)的氧化作用下实现二硫键交联凝胶，具有不需要添加交联剂，副产物为水，生产工艺简单以及不含杂质等许多优点，避免了当前交联透明质酸凝胶产品的复杂工艺及交联剂残余引起的潜在毒副作用，通过简单混合获得用于水针治疗的透明质酸凝胶组合物。
在上述的制备过程中，可对透明质酸巯基化衍生物水溶液和透明质酸的水溶液进行过滤除菌，然后在无菌条件下制备本发明所述的用于水光注射的透明质酸凝胶组合物，亦可采用终端灭菌等方式，终端灭菌方式可采用本领域技术人员所熟知的湿热灭菌等方法。
所述制备方法的另一种技术方案是：透明质酸巯基化衍生物水溶液与透明质酸水溶液进行物理混合得到混合溶液，然后经氧化过程形成二硫键交联，即得到本发明所述的用于水光注射的透明质酸凝胶组合物。氧化过程亦可在氧气的作用进行，如空气中的氧气和/或水溶液 中的溶解氧。
本制备方法通过简单混合获得透明质酸混合物，且透明质酸巯基化衍生物水溶液在氧气(空气中的氧气和/或水溶液中的溶解氧)的氧化作用下实现二硫键交联，具有不需要添加交联剂，副产物为水，生产工艺简单以及不含杂质等许多优点，避免了当前交联透明质酸凝胶产品的复杂工艺及交联剂残余引起的潜在毒副作用，获得透明质酸凝胶组合物。
制备过程亦可采用无菌工艺，或对所制备的透明质酸凝胶组合物进行终端灭菌。在该技术方案所制备的凝胶组合物中，非交联的透明质酸或其衍生物被物理包埋在二硫键交联透明质酸中，形成了本领域技术人员所熟知的半互穿网络的结构。
在本发明中，所述的用于水光注射的透明质酸凝胶组合物中还可以含有多种营养活性物质，如各种维生素、氨基酸、生长因子等，以实现协同的水光注射补水保湿等效果。营养活性物质可以溶解于透明质酸巯基化衍生物水溶液和/或透明质酸水溶液，然后根据上述两种制备方法即可制备含有营养物质的透明质酸凝胶组合物。
本发明的有益效果是：
本发明所述的用于水光注射的透密质酸凝胶组合物同时含有二硫键交联透明质酸和非交联的透明质酸，具有良好的流动性，易于通过水光针极细针头进行注射，可在皮下浅表层实现良好的均匀分布，不会出现鼓包现象，以及水光注射后补水保湿起效快且维持时间长等优点，可有效改善肌肤肤质。
发明所述的用于水光注射的透密质酸凝胶组合物兼具了二硫键交联透明质酸和非交联的透明质酸用于水光注射时的优点，有效解决了非交联透明质酸起效快但补水保湿持续时间较短以及二硫键交联透明质酸补水保湿持续时间长但起效时间滞后的问题。
本发明所述的用于水光注射的透密质酸凝胶组合物可方便地通过透明质酸巯基化衍生物水溶液和非交联透明质酸水溶液制备，具有不需要添加交联剂、制备工艺简单、不含杂质、易于添加其它营养活性物质等许多优点，避免了当前交联透明质酸凝胶产品的复杂工艺及交联剂残余引起的毒副作用。
根据本发明的制备方法通过透明质酸巯基化衍生物水溶液在氧气(空气中的氧气和/或水溶液中的溶解氧)的氧化作用下实现二硫键交联，具有不需要添加交联剂，副产物为水，生产工艺简单以及不含杂质等许多优点，避免了当前交联透明质酸凝胶产品的复杂工艺及交联剂残余引起的潜在毒副作用；通过简单混合获得本发明的透明质酸凝胶混合物。
图1.透明质酸钠凝胶组合物水光注射后对皮肤含水量的影响
图2.透明质酸钠凝胶组合物水光注射后对皮肤弹性的影响。
图3.透明质酸钠凝胶组合物水光注射后对皮肤皱纹深度的影响。
下面将结合实施例对本发明的实施方案进行详细描述，但是本领域技术人员将会理解，下列实施例仅用于说明本发明，而不应视为限定本发明的范围。
实施例1：二硫键交联透明质酸凝胶的制备
透明质酸巯基化衍生物以180KDa分子量的透明质酸钠为原料，采用Shu等所报道的方法制备(Shu等，Biomacromolecules 2002,3:1304-1311)，其巯基含量分别为24μmol/g、38μmol/g和57μmol/g。
将上述透明质酸巯基化衍生物溶解得到含量为6mg/mL或12mg/mL的水溶液，调节溶液pH值为7.4，除菌过滤后转移入无菌玻璃容器；室温密闭静置保存4周，溶液失去流动性并形成二硫键交联水凝胶。
实施例2：透明质酸凝胶组合物的制备
透明质酸钠(50KDa)溶解得到含量为12mg/mL的水溶液，调节溶液pH值为7.4，除菌过滤后待用。
将实施例1制备的二硫键交联透明质酸凝胶(12mg/mL)与上述透明质酸水溶液按照体积比1:11、1:5、1:3、1:2、1:1.4、1:0.5、1:0.3、1:0.2和1:0.091进行物理搅拌混合，即得到如下表所示配比的透明质酸凝胶组合物。
实施例3：透明质酸凝胶组合物的可注射性能评价
采用Derma
(德玛莎)2代水光注射仪，测试实施例2所制备透明质酸凝胶组合物通过常规水光注射针头(九针)的可注射性。当透明质酸凝胶组合物中二硫键交联透明质酸的含量为1mg/mL、2mg/mL、3mg/mL和4mg/mL时，具有良好的可注射性；而当含量≥5mg/mL时，则很难通过水光注射仪进行注射。
实施例4：透明质酸凝胶组合物稀释后的可注射性能评价
实施例2所制备的透明质酸凝胶组合物(二硫键交联透明质酸的含量别为：5mg/mL、8mg/mL、9mg/mL、10mg/mL和11mg/mL)与生理盐水按照体积比1:2进行物理混合稀释。稀释过程在两通接头连接的注射器中进行，其中一支注射器装有实施例2所制备的透明质酸凝胶组合物(1mL)，另一只注射器装有2mL生理盐水，往返推挤60～80次进行物理稀释混合。可采用较小直径的两通接头(如小于1mm)以达到更好的稀释混合效果。
采用Derma
(德玛莎)2代水光注射仪，测试稀释后的透明质酸凝胶组合物通过常规水光注射针头(九针)的可注射性。测试结果表明各稀释后的透明质酸凝胶组合物均具有良好的可注射性。
实施例5：透明质酸凝胶组合物的制备
透明质酸钠溶解得到含量为2mg/mL、4mg/mL、6mg/mL、8mg/mL或10mg/mL的水溶液，调节溶液pH值为7.4，除菌过滤后待用。所采用的透明质酸钠的分子量为1.6KDa、3KDa、8KDa、50KDa、180KDa、500KDa、800KDa、1,500KDa或2,700KDa，可以是其中任意一种分子量，也可以是其中任意两种或两种以上分子量按照任意重量比的组合。
将实施例1制备的二硫键交联透明质酸凝胶(6mg/mL)与上述透明质酸水溶液按照体积比1:1进行物理搅拌混合，即得到透明质酸凝胶组合物，其中二硫键交联透明质酸的含量为3mg/mL，透明质酸的含量为1mg/mL、2mg/mL、3mg/mL、4mg/mL或5mg/mL。
实施例6：透明质酸凝胶组合物的可注射性能评价
采用Derma
(德玛莎)2代水光注射仪，测试实施例5所制备透明质酸凝胶组合物通过常规水光注射针头(九针)的可注射性。测试结果表明各凝胶组合物均具有良好的可注射性。
实施例7：透明质酸凝胶组合物的制备
透明质酸巯基化衍生物以300KDa和1,500KDa分子量的透明质酸钠为原料，采用Shu等所报道的方法制备(Shu等，Biomacromolecules 2002,3:1304-1311)，其巯基含量分别为33μmol/g和40μmol/g。
将上述透明质酸巯基化衍生物和透明质酸钠共同溶解得到混合水溶液，其中透明质酸巯基化衍生物的含量为2.5mg/mL或5mg/mL，透明质酸钠的含量分别为1mg/mL、2mg/mL、3mg/mL、4mg/mL或5mg/mL。调节溶液pH值为中性，湿热灭菌后转移入无菌玻璃容器；室温密闭静置保存4周，溶液失去流动性并形成具有半互传网络结构的透明质酸凝胶组合物。
所采用的透明质酸钠的分子量为1.6KDa、3KDa、8KDa、50KDa、180KDa、500KDa、800KDa、1,500KDa或2,700KDa，可以是其中任意一种分子量，也可以是其中任意两种或两种分子量按照任意重量比的组合。
实施例8：透明质酸凝胶组合物的可注射性能评价
采用Derma
(德玛莎)2代水光注射仪，测试实施例7所制备透明质酸凝胶组合物通过常规水光注射针头(九针)的可注射性。测试结果表明各凝胶组合物均具有良好的可注射性。
实施例9：透明质酸凝胶组合物的吸水保水性能
采用与实施例4相同的稀释过程，将实施例7所制备的凝胶与生理盐水按照体积比1:2进行物理混合稀释，然后置入小玻璃瓶，室温静置1小时，均未观察到明显的水相与凝胶相的分层现象，表明凝胶具有良好的吸水保水性能。
实施例10：透明质酸凝胶组合物的水光注射效果评价
选取健康志愿者12名(分3组，每组4名)分别进行面部水光注射(Derma
2代水光注射仪，常规九针水光注射针头)，注射体积为5mL。
试验组使用的样品：实施例5制备的凝胶组合物，二硫键交联透明质酸的含量为3mg/mL(采用38μmol/g的巯基化衍生物制备)，非交联透明质酸钠的含量为2mg/mL(1,500KDa)。
对照组I使用的样品：5mg/mL的非交联透明质酸钠水溶液(分子量1.5MDa)。
对照组II使用的样品：与试验组使用的样品相同，但不含有非交联的透明质酸钠。
在面部水光注射后的不同时间点，分别在相同部位进行皮肤含水量测试以及皱纹和皮肤弹性的改善测试。
注射前后皮肤水分相对增加量(％)采用皮肤水分测定仪进行测试，注射前后皮肤弹性相对增加量(％)采用皮肤弹性测定仪进行测试，注射前后皱纹平均深度相对减少值采用快速三维成像系统进行评价。
本实施例的试验结果参见图1-3。与对照组I和对照组II相比较，交联透明质酸凝胶组合物具有更好水光治疗效果，起效快且维持时间长；同时试验组的所有试验对象均未发现鼓包现象，表明交联透明质酸凝胶组合物具有良好的流动性，可在水光注射的浅表层均匀分布。
上述实施例为本发明较佳的实施方式，但本发明的实施方式并不受实施例的限制，其它任何未背离本发明的精神实质与原理下所做的改变、修饰、组合、替代、简化均应为等效替换方式，都包含在本发明的保护范围之内。
Claims (21)
- 一种用于水光注射的透明质酸凝胶组合物，其特征在于，该透明质酸凝胶组合物含有：1)二硫键交联透明质酸，且其含量不大于10mg/mL；和2)非交联的透明质酸。
- 根据权利要求1所述的用于水光注射的透明质酸凝胶组合物，其特征在于，所述的二硫键交联透明质酸的含量在1～4mg/mL之间。
- 根据权利要求2所述的用于水光注射的透明质酸凝胶组合物，其特征在于，所述的二硫键交联透明质酸的含量在2～3mg/mL之间。
- 根据权利要求1所述的用于水光注射的透明质酸凝胶组合物，其特征在于，所述的二硫键交联透明质酸通过透明质酸巯基化衍生物制备。
- 根据权利要求4所述的用于水光注射的透明质酸凝胶组合物，其特征在于，所述的透明质酸巯基化衍生物的巯基含量为10～50μmol/g。
- 根据权利要求5所述的用于水光注射的透明质酸凝胶组合物，其特征在于，所述透明质酸巯基化衍生物的巯基含量为20～40μmol/g。
- 根据权利要求1所述的用于水光注射的透明质酸凝胶组合物，其特征在于，所述的非交联的透明质酸的含量小于10mg/mL。
- 根据权利要求7所述的用于水光注射的透明质酸凝胶组合物，其特征在于，所述的非交联的透明质酸的含量在1～5mg/mL之间。
- 根据权利要求8所述的用于水光注射的透明质酸凝胶组合物，其特征在于，所述的非交联的透明质酸的含量在2～4mg/mL之间。
- 根据权利要求1所述的用于水光注射的透明质酸凝胶组合物，其特征在于，所述的非交联的透明质酸分子量在800KDa～3,000KDa之间。
- 根据权利要求10所述的用于水光注射的透明质酸凝胶组合物，其特征在于，所述的非交联的透明质酸分子量在1,000KDa～2,800KDa之间。
- 根据权利要求1所述的用于水光注射的透明质酸凝胶组合物，其特征在于，所述的非交联的透明质酸包括两种及两种以上不同的分子量。
- 根据权利要求12所述的用于水光注射的透明质酸凝胶组合物，其特征在于，至少一种所述的非交联的透明质酸的分子量在1.6KDa～500KDa之间且其中至少一种所述的非交联的透明质酸的分子量在800KDa～3,000KDa之间。
- 根据权利要求13所述的用于水光注射的透明质酸凝胶组合物，其特征在于，至少一种所述的非交联的透明质酸的分子量在2.4～8KDa之间且其中至少一种所述的非交联的透明质酸 的分子量在1,000KDa～2,800KDa之间。
- 根据权利要求1所述的用于水光注射的透明质酸凝胶组合物，其特征在于，所述的用于水光注射的透明质酸凝胶组合物具有半互穿网络结构。
- 根据权利要求1-15之一所述的用于水光注射的透明质酸凝胶组合物，其特征在于，所述的用于水光注射的透明质酸凝胶组合物含有营养活性物质。
- 根据权利要求16所述的用于水光注射的透明质酸凝胶组合物，其特征在于，所述的营养活性物质包括维生素、氨基酸、生长因子等。
- 一种根据权利要求1-17之一所述的用于水光注射的透明质酸凝胶组合物的制备方法，其特征在于，该制备方法包括如下过程：透明质酸巯基化衍生物溶解得到水溶液，并经氧化过程得到二硫键交联透明质酸凝胶，然后与透明质酸的水溶液进行物理混合。
- 一种根据权利要求1-17之一所述的用于水光注射的透明质酸凝胶组合物的制备方法，其特征在于，该制备方法包括如下过程：透明质酸巯基化衍生物水溶液与透明质酸水溶液进行物理混合得到混合溶液，然后经氧化过程形成二硫键交联。
- 根据权利要求18或19所述的用于水光注射的透明质酸凝胶组合物的制备方法，其特征在于，所述的氧化过程在氧气的作用下进行。
- 根据权利要求20所述的用于水光注射的透明质酸凝胶组合物的制备方法，其特征在于，所述的氧气是指空气中的氧气和/或水溶液中的溶解氧。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911008648.2 | 2019-10-23 | ||
| CN201911008648.2A CN110812270B (zh) | 2019-10-23 | 2019-10-23 | 一种用于水光注射的透明质酸凝胶组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021077681A1 true WO2021077681A1 (zh) | 2021-04-29 |
Family
ID=69550054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2020/082546 WO2021077681A1 (zh) | 2019-10-23 | 2020-03-31 | 一种用于水光注射的透明质酸凝胶组合物及其制备方法 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110812270B (zh) |
| WO (1) | WO2021077681A1 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117180494A (zh) * | 2023-11-07 | 2023-12-08 | 四川大学 | 可减少纤维化瘢痕产生的可注射多糖水凝胶及其制备方法 |
| CN117298355A (zh) * | 2023-11-28 | 2023-12-29 | 常州百瑞吉生物医药股份有限公司 | 一种包裹性透明质酸凝胶组合物及其制备方法与应用 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110812270B (zh) * | 2019-10-23 | 2021-09-17 | 常州百瑞吉生物医药有限公司 | 一种用于水光注射的透明质酸凝胶组合物及其制备方法 |
| CN114288207A (zh) * | 2021-12-31 | 2022-04-08 | 常州百瑞吉生物医药有限公司 | 一种具有补水且高保湿功能的组合物及其应用 |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101502678A (zh) * | 2008-02-04 | 2009-08-12 | 山东省药学科学院 | 一种注射用混合凝胶及其制备方法 |
| CN101721349A (zh) * | 2008-10-16 | 2010-06-09 | 常州百瑞吉生物医药有限公司 | 可注射原位交联水凝胶及其制备方法和用途 |
| CN102399295A (zh) * | 2010-09-09 | 2012-04-04 | 常州百瑞吉生物医药有限公司 | 低巯基化改性度生物相容高分子巯基化衍生物及其交联材料和用途 |
| CN105131348A (zh) * | 2015-08-19 | 2015-12-09 | 李媚 | 一种无菌可注射材料 |
| CN105233270A (zh) * | 2015-11-12 | 2016-01-13 | 上海昊海生物科技股份有限公司 | 用于水光治疗的药物组合物及其应用 |
| CN108261341A (zh) * | 2018-02-12 | 2018-07-10 | 苏州纳晶医药技术有限公司 | 双组份用于纠正皮肤皱纹的美白长效水光针剂 |
| CN109010912A (zh) * | 2018-09-27 | 2018-12-18 | 福建拓烯新材料科技有限公司 | 一种改性的玻尿酸可注射填充材料及其制备方法 |
| CN110812270A (zh) * | 2019-10-23 | 2020-02-21 | 常州百瑞吉生物医药有限公司 | 一种用于水光注射的透明质酸凝胶组合物及其制备方法 |
| CN110812253A (zh) * | 2019-10-23 | 2020-02-21 | 常州百瑞吉生物医药有限公司 | 一种用于水光注射的透明质酸凝胶及其使用方法 |
-
2019
- 2019-10-23 CN CN201911008648.2A patent/CN110812270B/zh active Active
-
2020
- 2020-03-31 WO PCT/CN2020/082546 patent/WO2021077681A1/zh active Application Filing
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101502678A (zh) * | 2008-02-04 | 2009-08-12 | 山东省药学科学院 | 一种注射用混合凝胶及其制备方法 |
| CN101721349A (zh) * | 2008-10-16 | 2010-06-09 | 常州百瑞吉生物医药有限公司 | 可注射原位交联水凝胶及其制备方法和用途 |
| CN102399295A (zh) * | 2010-09-09 | 2012-04-04 | 常州百瑞吉生物医药有限公司 | 低巯基化改性度生物相容高分子巯基化衍生物及其交联材料和用途 |
| CN105131348A (zh) * | 2015-08-19 | 2015-12-09 | 李媚 | 一种无菌可注射材料 |
| CN105233270A (zh) * | 2015-11-12 | 2016-01-13 | 上海昊海生物科技股份有限公司 | 用于水光治疗的药物组合物及其应用 |
| CN108261341A (zh) * | 2018-02-12 | 2018-07-10 | 苏州纳晶医药技术有限公司 | 双组份用于纠正皮肤皱纹的美白长效水光针剂 |
| CN109010912A (zh) * | 2018-09-27 | 2018-12-18 | 福建拓烯新材料科技有限公司 | 一种改性的玻尿酸可注射填充材料及其制备方法 |
| CN110812270A (zh) * | 2019-10-23 | 2020-02-21 | 常州百瑞吉生物医药有限公司 | 一种用于水光注射的透明质酸凝胶组合物及其制备方法 |
| CN110812253A (zh) * | 2019-10-23 | 2020-02-21 | 常州百瑞吉生物医药有限公司 | 一种用于水光注射的透明质酸凝胶及其使用方法 |
Non-Patent Citations (2)
| Title |
|---|
| LIU, Y.C. ET AL.: "Biocompatibility and stability of disulfide-crosslinked hyaluronan films", BIOMATERIALS, vol. 26, 31 December 2005 (2005-12-31), pages 4737 - 4746, XP025280873, DOI: 10.1016/j.biomaterials.2005.01.003 * |
| SHU, X.Z. ET AL.: "Disulfide-crosslinked hyaluronan-gelatin hydrogel films: a covalent mimic of the extracellular matrix for in vitro cell growth", BIOMATERIALS, vol. 24, 31 December 2003 (2003-12-31), pages 3825 - 3834, XP004431163, DOI: 10.1016/S0142-9612(03)00267-9 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117180494A (zh) * | 2023-11-07 | 2023-12-08 | 四川大学 | 可减少纤维化瘢痕产生的可注射多糖水凝胶及其制备方法 |
| CN117180494B (zh) * | 2023-11-07 | 2024-01-23 | 四川大学 | 可减少纤维化瘢痕产生的可注射多糖水凝胶及其制备方法 |
| CN117298355A (zh) * | 2023-11-28 | 2023-12-29 | 常州百瑞吉生物医药股份有限公司 | 一种包裹性透明质酸凝胶组合物及其制备方法与应用 |
| CN117298355B (zh) * | 2023-11-28 | 2024-03-08 | 常州百瑞吉生物医药股份有限公司 | 一种包裹性透明质酸凝胶组合物及其制备方法与应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110812270B (zh) | 2021-09-17 |
| CN110812270A (zh) | 2020-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021077681A1 (zh) | 一种用于水光注射的透明质酸凝胶组合物及其制备方法 | |
| WO2021077683A1 (zh) | 一种用于水光注射的透明质酸凝胶及其使用方法 | |
| JP2020179280A (ja) | 抗酸化物質を含む皮膚充填剤組成物 | |
| JP2019058692A (ja) | 酸化防止剤を含む皮膚充填剤組成物 | |
| ES2822649T3 (es) | Composiciones de relleno dérmico a base de ácido hialurónico/colágeno y métodos para obtener las mismas | |
| US8153612B2 (en) | Injectable chitosan mixtures forming hydrogels | |
| EP2121026B1 (en) | Novel injectable chitosan mixtures forming hydrogels | |
| EP2892575B1 (en) | Hyaluronic acid/collagen- based dermal filler compositions and methods for making same | |
| EP2405936B1 (en) | Injectable biomaterials | |
| KR20140108260A (ko) | 진피 필러 조성물 | |
| JP6827108B2 (ja) | 皮膚充填剤用途のためのコアセルベートヒアルロナンヒドロゲル | |
| CN111297727A (zh) | 一种美塑治疗组合物及其应用 | |
| WO2021018950A1 (en) | Cosmetic composition with combined filler and skin regenerative effect | |
| TWI722443B (zh) | 用於照護及/或保養皮膚與延緩及/或抑制皮膚老化的生醫組成物及其用途 | |
| JP2021072906A (ja) | 皮膚充填剤用途のためのコアセルベートヒアルロナンヒドロゲル | |
| Devi et al. | Significance of hyaluronic acid in the biomedical field: A review | |
| CN115944553A (zh) | 寡肽在提高交联透明质酸或其盐稳定性中的应用 | |
| CN115869250A (zh) | 一种注射用透明质酸或透明质酸钠组合物及其制备方法和用途 | |
| CN118058993A (zh) | 注射用复合营养溶液及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20880230 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20880230 Country of ref document: EP Kind code of ref document: A1 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20880230 Country of ref document: EP Kind code of ref document: A1 |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 12.12.2022). |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20880230 Country of ref document: EP Kind code of ref document: A1 |